- Home
- PMM vs LRMR Comparison
PMM vs LRMR Comparison
Compare PMM & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | LRMR |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.3M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PMM | LRMR |
|---|---|---|
| Price | $6.32 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.29 |
| AVG Volume (30 Days) | 88.4K | ★ 6.3M |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.66 | $1.61 |
| 52 Week High | $6.52 | $6.42 |
Technical Indicators
Market Signals| Indicator | PMM | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 47.22 |
| Support Level | $6.06 | $3.13 |
| Resistance Level | $6.36 | $4.50 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 25.94 | 4.55 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.